INTEGRA LIFESCIENCES HOLDINGS CORP · Surgical & Medical Instruments & Apparatus

IART

Moderate riskNext report: Around Feb 25, 2027 (est.)

View price ↗

The short version

A company still losing money with steady sales.

Going well

Buying back shares: share count down 8.2% in 3 years

Watch out for

Losing money, losses are large next to sales

Money moves

No insider buying or selling in the last 30 days
Institutions cut 1.8% from their holdings in the quarter ending June 2026 (114 bought, 93 sold)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$12.11+1.7% that day

Company value: $942M; Share price times all shares
Price vs profit (P/E): 71.2x; You pay about $71 for each $1 of yearly profit
Price vs sales: 0.57x; Company value is 0.57 times a year of sales
Cash vs value: 27%; Cash as a share of company value
Debt vs value: 77%; Debt as a share of company value

From IART's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Sep '26

$411.2M+2.3% vs a year earlier

Dec '23Tap a barSep '26

Last 12 months: $1.7B, up 0.8% from the 12 months before. Over 5 years, sales grew about 3.6% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of IART. Starting points are the company's recent numbers.

Sales growth+1% a yearRecently: +0.8% a yearProfit margin1%Last 12 months: 0.8%P/E at the end40xToday: 71.2x. Many steady companies trade at 12x to 25xShare count change-3% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$1.7B

Profit in 5 years$17M

Price these guesses point to$10.43-14% vs $12.11 todayAbout -3.0% a year, before dividends

What today's price needs: with a 1% margin and a 40x P/E, sales would have to grow about 4.1% a year for 5 years just to match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

1/6Weak

MissReturn on equity 15%+Earns a lot on the money owners have in the business.-39.9%
MissDebt under half of equityNot relying on borrowed money.0.70x equity
MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.-31.6%
MissProfitable every yearSteady profits, not one good year.8 of 10 years
MissFree cash flow positiveBrings in more cash than it spends to run and grow.-$31.1M
PassShare count not growingNot diluting owners. Falling means buybacks.-8.2% in 3 years

Revenue: $1.6B; +1.5% vs prior year
5-year growth: +3.6%/yr; revenue, per year
Total debt: $726.6M; 0.70x equity
Current ratio: 2.54x; short-term assets / bills due

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: gross margin 40%+. A checklist is a starting point for research, not a verdict.

Latest quarter

Quarter ended Sep 30, 2026

Reported Oct 21Before open6:15 am ET

Revenue: $411.2M; +2.3% YoY
EPS: $0.19; vs -$0.07
Op. margin: 4.6%; +1.7 pts
Gross margin: 51.0%; -0.5 pts
Free cash flow: $85.7M
Share count: +2.4%; vs a year ago

Insider rating

Last 90 days

No open-market insider buys or sells in the last 90 days.

Weekly insider trend

No trades to chart yet.

Filing buzz

Last 7 days vs normal

70/ 100

This week: 2
Normal week: 0.9
vs normal: 2.3x

SEC filings of any kind. 50 means a normal week.

Institutional ownership

Steady-1.8%

Institutions cut 1.8% from their holdings. 114 bought, 93 sold. 2 quarters of net selling in a row.

Shares held by institutions73.4M

Sep '24Jun '26

Safety check

From SEC filings

Share count growthYearly rate, last 3 years

-0.2%

Cash runwayAt last year's cash burn

Cash flow positive

Debt to equityLatest balance sheet: debt compared with what owners have

0.7x · $697.5M debt

Shares outstandingLatest reported

78M

Why moderate risk

Losing money, losses are large next to sales

Earnings reports

Last 12

Next reportAround Feb 25, 2027 (est.)Estimated from the same quarter last year

Results filedOct 21
Results filedOct 2
Results filedJul 29
Results filedMay 5
Results filedFeb 26

Flags and big holders

Offerings 6 months, flags 12 months, holders 90 days

5%+ holder update (passive)Aug 13 · View filing ↗Big holder New 5%+ holder (passive)Jul 31 · View filing ↗Big holder

Insider trades

Open-market buys and sells, last 90 days

No open-market buys or sells in 90 days. Grants and option exercises are left out.

"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.

Latest filings

Straight from SEC EDGAR

Quarterly reportOct 23 · Form 10-Q ↗Earnings resultsOct 21 · Form 8-K ↗Major agreementOct 19 · Form 8-K ↗New insiderOct 13 · Form 3 ↗Investor disclosureOct 9 · Form 8-K ↗Earnings resultsOct 2 · Form 8-K ↗New insiderSep 28 · Form 3 ↗Investor disclosureSep 8 · Form 8-K ↗

Shares withheld for taxesChantal Veillon-bertelootEVP & CHRO

1,455 shares at $16.62 · $24K

-7% of holdings
Now owns 20,772 shares
Filed 3 days after trade

Sep 1Form 4 ↗

5%+ holder update (passive)Aug 13 · Form SCHEDULE 13G/A ↗New 5%+ holder (passive)Jul 31 · Form SCHEDULE 13G ↗Earnings resultsJul 29 · Form 8-K ↗Quarterly reportJul 29 · Form 10-Q ↗

Shares withheld for taxesLea Daniels KnightEVP & Chief Financial Officer

5,226 shares at $18.05 · $94K

-10% of holdings
Now owns 45,263 shares
Filed 3 days after trade

Jul 3Form 4 ↗

Stock awardRobert T. Jr. DavisEVP & President, TR&DT

11,180 shares

+26% of holdings
Now owns 54,530 shares
Restricted Stock Units
Filed 5 days after trade

Jul 1Form 4 ↗

Source: SEC EDGAR filings. For informational purposes. Not investment advice.

Report a problem with this page